We are live on
!
Find out more
Walleye Capital Portfolio holdings
AUM
$24B
1-Year Est. Return
37.67%
This Fund
S&P 500
This Quarter
Est. Return
-0.19%
1 Year Est. Return
+37.67%
3 Year Est. Return
+98.01%
5 Year Est. Return
+160%
10 Year Est. Return
–
AUM
$24B
AUM Growth
-$8.57B
(-26%)
Cap. Flow
-$8.5B
Cap. Flow
% of AUM
-35.37%
Top 10 Holdings %
Top 10 Hldgs %
32.92%
Holding
5,150
New
660
Increased
1,270
Reduced
2,242
Closed
835
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$948M |
| 2 |
Amazon
AMZN
|
+$264M |
| 3 |
iShares Bitcoin Trust
IBIT
|
+$138M |
| 4 |
Apple
AAPL
|
+$111M |
| 5 |
Doximity
DOCS
|
+$72.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$778M |
| 2 |
Intuitive Surgical
ISRG
|
+$110M |
| 3 |
Boston Scientific
BSX
|
+$96.4M |
| 4 |
Cummins
CMI
|
+$90.4M |
| 5 |
Microsoft
MSFT
|
+$77.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 9.1% |
| 2 | Consumer Discretionary | 7.52% |
| 3 | Industrials | 5.58% |
| 4 | Financials | 4.45% |
| 5 | Healthcare | 4.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3926
ACM Research
ACMR
$5.53B
| $34.3K | ﹤0.01% |
871
-5,354
| -86% | -$284K |
|
3927
AbCellera Biologics
ABCL
$1.6B
| $34.1K | ﹤0.01% |
9,780
-239,270
| -96% | -$861K |
|
3928
PUT
Axsome Therapeutics
AXSM
$12.3B
| $33.8K | ﹤0.01% |
200
-600
| -75% | -$104K |
|
3929
CALL
Altimmune
ALT
$576M
| $33.3K | ﹤0.01% |
10,800
-53,600
| -83% | -$228K |
|
3930
Crocs
CROX
$6.69B
| $33.2K | ﹤0.01% |
400
-33,653
| -99% | -$2.88M |
|
3931
CALL
Cactus
WHD
$3.74B
| $33.2K | ﹤0.01% |
+700
| New | +$36.7K |
|
3932
CALL
Robert Half
RHI
$4.07B
| $33K | ﹤0.01% |
1,300
-39,700
| -97% | -$1.05M |
|
3933
PUT
Iovance Biotherapeutics
IOVA
$2.19B
| $33K | ﹤0.01% |
9,400
-22,300
| -70% | -$71.3K |
|
3934
CALL
Arcutis Biotherapeutics
ARQT
$3.48B
| $33K | ﹤0.01% |
1,400
-38,600
| -97% | -$985K |
|
3935
PUT
JFrog
FROG
$9.84B
| $32.9K | ﹤0.01% |
700
-29,600
| -98% | -$1.45M |
|
|
ESPR
3936
CALL
DELISTED
Esperion Therapeutics
ESPR
| $32.6K | ﹤0.01% |
11,900
-147,800
| -93% | -$468K |
|
3937
Canadian Natural Resources
CNQ
$93.4B
| $32.6K | ﹤0.01% |
+668
| New | +$27.5K |
|
3938
PUT
Glaukos
GKOS
$8.92B
| $32.3K | ﹤0.01% |
+300
| New | +$33.8K |
|
3939
PUT
Criteo
CRTO
$1.05B
| $32.3K | ﹤0.01% |
1,800
| – | – |
|
3940
PUT
Intellia Therapeutics
NTLA
$1.49B
| $32K | ﹤0.01% |
2,500
-9,900
| -80% | -$126K |
|
|
MBAVW
3941
DELISTED
M3-Brigade Acquisition V Corp Warrant
MBAVW
| $31.4K | ﹤0.01% |
105,350
-5,000
| -5% | -$3.4K |
|
3942
Onfolio Holdings Warrant
ONFOW
$71.4K
| $31K | ﹤0.01% |
506,945
| – | – |
|
|
GRAL
3943
PUT
GRAIL Inc
GRAL
$2.87B
| $31K | ﹤0.01% |
600
-5,600
| -90% | -$434K |
|
3944
CALL
Ironwood Pharmaceuticals
IRWD
$644M
| $30.9K | ﹤0.01% |
+8,800
| New | +$36.1K |
|
|
TPC
3945
PUT
Tutor Perini Cor
TPC
$4.51B
| $30.9K | ﹤0.01% |
400
-4,700
| -92% | -$360K |
|
3946
CALL
Extreme Networks
EXTR
$3.92B
| $30.2K | ﹤0.01% |
+2,000
| New | +$29.9K |
|
|
BACCR
3947
Blue Acquisition Corp Right
BACCR
| $30K | ﹤0.01% |
100,000
| – | – |
|
|
ALUB.WS
3948
Alussa Energy Acquisition Corp II Warrants
ALUB.WS
| $29.9K | ﹤0.01% |
+83,168
| New | +$38.4K |
|
3949
PUT
Waters Corp
WAT
$36.4B
| $29.8K | ﹤0.01% |
+100
| New | +$34.2K |
|
3950
Fortuna Silver Mines
FSM
$2.59B
| $29.7K | ﹤0.01% |
+2,991
| New | +$32.4K |
|
Similar funds
JG
SC
OAG
CS
Walleye Capital's Q1 2026 Portfolio in Review
As of Q1 2026, Walleye Capital held 5,150 positions worth $24B, down 26% from $32.6B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Walleye Capital withdrew a net $8.5B in Q1 2026, closing 835 positions and reducing 2,242 holdings. Its most notable exit was Repligen, an estimated $68.3M position sold in full.
By sector, the portfolio is most concentrated in Technology at 9.1% of assets, up from 7.3% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Walleye Capital opened a new position in Texas Roadhouse worth $51.4M.
- Walleye Capital's largest Q1 2026 buy was Texas Roadhouse: 311,416 shares worth $51.4M.
- Walleye Capital added most to State Street SPDR S&P 500 ETF Trust in Q1 2026, an estimated $948M increase.
- Walleye Capital's biggest Q1 2026 reduction was iShares Core S&P 500 ETF, cutting an estimated $778M.
- Walleye Capital fully exited Repligen in Q1 2026, selling an estimated $68.3M.
- Walleye Capital's ten largest holdings make up 33% of its $24B portfolio in Q1 2026.
- Walleye Capital opened 660 new positions and closed 835 in Q1 2026.
- Walleye Capital's portfolio value fell 26% quarter-over-quarter to $24B.
Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.